CN108144064B - Dihydromyricetin medicament taking aggregate of Tween80 and chitosan as carrier and preparation method thereof - Google Patents
Dihydromyricetin medicament taking aggregate of Tween80 and chitosan as carrier and preparation method thereof Download PDFInfo
- Publication number
- CN108144064B CN108144064B CN201810123231.XA CN201810123231A CN108144064B CN 108144064 B CN108144064 B CN 108144064B CN 201810123231 A CN201810123231 A CN 201810123231A CN 108144064 B CN108144064 B CN 108144064B
- Authority
- CN
- China
- Prior art keywords
- chitosan
- dihydromyricetin
- water
- release
- tween80
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 176
- 229920001661 Chitosan Polymers 0.000 title claims abstract description 88
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 title claims abstract description 55
- 229920000053 polysorbate 80 Polymers 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 90
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000003756 stirring Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 239000012154 double-distilled water Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 238000010587 phase diagram Methods 0.000 abstract description 5
- 238000009792 diffusion process Methods 0.000 abstract description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000001988 small-angle X-ray diffraction Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 description 28
- 239000004973 liquid crystal related substance Substances 0.000 description 21
- 239000003921 oil Substances 0.000 description 17
- 230000006399 behavior Effects 0.000 description 13
- 239000004976 Lyotropic liquid crystal Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 9
- 238000011179 visual inspection Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000000235 small-angle X-ray scattering Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a dihydromyricetin medicament based on an aggregate of polyoxyethylene sorbitan monooleate and chitosan as a carrier and a preparation method thereof, the medicament prepared by the application consists of dihydromyricetin, polyoxyethylene sorbitan monooleate, chitosan, isopropyl myristate and water, the sample type characterization is carried out by a phase diagram method and small-angle X-ray diffraction, the content of chitosan, the influence of oil content and water content, the pH value of a system influencing the release of dihydromyricetin are obtained, the chitosan is dissolved in the system and forms a stable aggregate, the coordination and the coordination of all components of the prepared medicament can achieve the effect of controlling the release rate of the dihydromyricetin medicament, and fitting a release curve by using different release kinetics models, and finding that the release process is relatively consistent with first-order kinetics, which indicates that the release of the dihydromyricetin in the sample is caused by concentration diffusion.
Description
Technical Field
The invention belongs to the technical field of medicament preparation, and particularly relates to a dihydromyricetin medicament taking aggregates of Tween80 and chitosan as carriers and a preparation method thereof.
Background
Dihydromyricetin (DMY) is a compound of natural flavone extracted from plants, and has been widely noticed due to numerous physiological activities, such as protecting liver, regulating blood lipid, resisting bacteria, resisting oxidation, etc. However, its solubility in water is poor (0.2mg/mL,25 ℃), resulting in low bioavailability, which greatly limits practical use. In recent years, in order to improve the above problems of DMY, it has been studied to increase the solubility of DMY by solubilizing a drug by entrapping DMY with a drug carrier such as microemulsion, liposome, micelle, or the like.
The surfactant is an amphiphilic organic compound with a hydrophilic head group and a hydrophobic tail, the hydrophobic tails of molecules are mutually associated to form micelles, and when the concentration of the surfactant exceeds the value, the micelle aggregates can be spontaneously formed in aqueous solution. When the inner micelles aggregate to a certain critical level, a lyotropic liquid crystalline phase will exist. Structurally, the structure is a short-range disordered and long-range ordered aggregate. The liquid crystal material is mainly divided into a hexagonal phase, a lamellar phase and a cubic phase liquid crystal, wherein the hexagonal phase is formed by orderly arranging rod-shaped micelles in two dimensions, oil-soluble substances can be solubilized in a hydrophobic core of the liquid crystal material, and water-soluble compounds can be solubilized in a hydrophilic area of the liquid crystal material.
However, the lyotropic liquid crystal is generally selected from a biocompatible carrier system which is green and low in toxicity and harmless to organisms, so that amphiphilic molecules which are non-toxic, biodegradable and biocompatible are selected for constructing the target lyotropic liquid crystal. Among them, polyoxyethylene sorbitan fatty acid derivative (Tween80), which is a non-ionic surfactant with mild properties and slightly bitter taste, is frequently used as an emulsifier and solubilizer and is widely used in drug delivery systems. Research shows that the Tween80 as surfactant can constitute lyotropic liquid crystal as medicine carrier, can solubilize curcumin as insoluble medicine, raise the solubility of medicine and protect unstable curcumin in light and heat condition, so that Tween80 may be used as ideal surfactant for constituting ordered aggregate of lyotropic liquid crystal, etc.
Chitosan is a naturally occurring high-molecular saccharide, is the only alkaline mucopolysaccharide in nature, widely exists in bodies of marine organisms such as shrimps and crabs, and also exists in cell walls of some fungi. Chitosan has the characteristics of no toxicity, easy degradation and the like, and has physiological activities of antibiosis, antioxidation and the like, so the chitosan is widely applied to food, medicine and cosmetics. However, the structure of chitosan itself results in poor water solubility, which seriously hinders its practical application. In recent years, chitosan is modified into a chitosan derivative by an organic reaction or the like, so that the solubility of chitosan is improved and the application range thereof is expanded. The chitosan structure has hydrophilic and hydrophobic groups and has certain self-aggregation capability, and the practical application of the chitosan is limited due to poor solubility.
Isopropyl myristate (IPM) is a food grade additive, frequently used as a penetrant and solubilizer in topical and transdermal drug delivery systems in drug delivery systems, and is widely used in the cosmetic industry and in drug delivery systems. In previous reports, isopropyl myristate has been shown not only to solubilize drugs in large quantities, but also not to damage skin during use, when used as a penetrant for transdermal administration.
Disclosure of Invention
In view of the problems in the prior art, it is an object of the present invention to provide a dihydromyricetin preparation based on aggregates of Tween80 and chitosan as carriers. The viscosity of lyotropic liquid crystal constructed based on Tween80 is higher, the solubility of dihydromyricetin is improved by the lyotropic liquid crystal arranged in a microstructure, non-toxic chitosan with various physiological functions is introduced to participate in the construction of the aggregate, the viscosity and the stability of the aggregate are increased by the introduction of the chitosan, and the influence of the introduction of the chitosan on the behaviors such as lyotropic liquid crystal phase behavior and release is further researched.
In order to solve the technical problems, the technical scheme of the invention is as follows:
a dihydromyricetin preparation based on polyoxyethylene sorbitan monooleate (Tween80) and chitosan (WCS) aggregate as carrier comprises dihydromyricetin, Tween80, chitosan (WCS), isopropyl myristate (IPM) and water. The concentration of the dihydromyricetin is 1.5mg/g, a carrier system is composed of Tween80, WCS, IPM and water, and the carrier system comprises 34-44 parts of Tween80, 0-8 parts of WCS, 2-11 parts of IPM and 45-53 parts of water by mass; where the mass of the WCS is not 0.
Tween80 and WCS are surfactants; isopropyl myristate is used as oil phase.
The ratio of surfactant to oil phase was 4: 1.
The pH of the agent was 7.4.
The solubility of the chitosan is 0.04 g/g.
A method for preparing dihydromyricetin medicament based on Tween80 and chitosan aggregate as carrier comprises: the method comprises the following specific steps:
1) stirring and uniformly mixing Tween80 and IPM in a water bath according to a certain mass ratio;
2) adding dihydromyricetin into the mixture obtained in the step 1), and stirring and uniformly mixing in a water bath;
3) adding WCS into the mixture obtained in the step 2), mixing and placing the mixture into a colorimetric tube, and uniformly dispersing the WCS in Tween 80;
4) dropwise adding secondary distilled water into the colorimetric tube obtained in the step 3), uniformly stirring by using a magnetic stirrer, and then placing in a water bath for balancing to obtain the medicament.
Preferably, the mass ratio of the Tween80 to the chitosan in the step 1) is 9: 2-10: 1.
preferably, the temperature of step 1) is 60-70 ℃.
Preferably, the water is added in multiple times in the step 4);
further preferably, the mass of the water in the step 4) is divided into a plurality of parts on average, and the mass part of the water added in each time is two parts (for example, the mass part of the water in the carrier is 45 parts, and the mass part of the water in the carrier is 2 parts in each time).
Preferably, the temperature of the water bath in the step 3) is 25 ℃.
Surfactant (b): tween80 as surfactant in the form of intermediate phase of lyotropic liquid crystal in water solution with hexagonal phase structure, chitosan as surfactant, and Tween80
The oil phase has the following functions: the increase of the IPM content of the oil phase causes the swelling of the hydrophobic core, the loose structure of the aggregate and the reduction of viscoelasticity, so that the DMY is released quickly.
Function of chitosan: the introduction of chitosan, especially at high chitosan content, has higher elasticity and more stable structure, thus resulting in slower release rate of DMY.
The function of water: the increase of the water content is beneficial to the formation of hydrogen bonds and the extension of chitosan, and the release rate of DMY is promoted to be slow.
Effect of pH: under the acidic condition, the protonation of amino groups in the chitosan is promoted, the repulsion between molecules is increased, the aggregate structure is loosened, and the release of DMY is promoted.
From the analysis, the viscoelasticity of the system influences the release of DMY, IPM can reduce the viscoelasticity of the solution, the structure is loose, the release of DMY is promoted, the viscoelasticity of the aggregate can be increased by chitosan, a better slow release effect is achieved, and the chitosan and water have the effect of promoting the formation of hydrogen bonds.
Under acidic conditions, the amino group of the chitosan is protonated, and further, the aggregate structure is influenced to a certain extent. The aggregate structure is loosened.
The invention has the beneficial effects that:
1) tween 80/WCS/IPM/H of the application2The coordination of all the components in the O system has solubilization effect on the dihydromyricetin and has slow release and controlled release effects on the release of the dihydromyricetin;
2) tween 80/WCS/IPM/H of the application2O improves the solubility of chitosan;
3) the result shows that the introduction of the chitosan increases the stability of the drug-loaded sample, prolongs the release time of the DMY in the sample and has good slow release effect on the DMY.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this application, illustrate embodiments of the application and, together with the description, serve to explain the application and are not intended to limit the application.
FIG. 1 shows Tween 80/chitosan (10:1, wt: wt)/IPM/H2O system is similar to a ternary phase diagram (25 ℃); wherein the mass ratio of the Tween80 to the chitosan is 1:0(a),10:1(b),9:2(c)
FIG. 2 shows a sample (S) at 25 ℃0And S1) Spectrum of SAXS
FIG. 3 shows the construction of Tween 80/chitosan/IPM/H with different chitosan contents (0%, 4%, 8%) of dihydromyricetin2Release Profile in O System (25 ℃ C.)
FIG. 4(a) Dihydromyricetin samples (S) were constructed at different surfactant (Tween 80/chitosan) and IPM contents (8:2,9:1,9.5:0.5)1O1,S1O2,S1O3) Release profile (25 ℃); (b) samples (S) constructed with dihydromyricetin at different water contents (45%, 49%, 53%)1W1,S1W2,S1W3) Release Curve (25 ℃ C.)
FIG. 5 shows the concentration of dihydromyricetin in samples (S) at different pH2) Release Curve (25 ℃ C.)
FIG. 6 (a) Dihydromyricetin/liquid Crystal (S)1) White liquid crystal (BS)1) DMY infrared spectrum (DMY), and (b) dihydromyricetin/liquid crystal samples with different chitosan contents (S)1,S2,S3) Infrared spectrogram
FIG. 7 (a) Dihydromyricetin/liquid Crystal samples (S) constructed with different Tween80: Chitosan/IPM content1O1,S1O2,S1O3) Infrared spectrum, (b) dihydromyricetin/liquid crystal sample (S) under different water content1W1,S1W2,S1W3) Infrared spectrogram
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments according to the present application. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
Polyoxyethylene sorbitan monooleate (Tween80, national drug group chemical reagent Co., Ltd.), isopropyl myristate (IPM, national drug group chemical reagent Co., Ltd.), chitosan (WCS, degree of deacetylation > 85%, Cinan Haidebei ocean bioengineering Co., Ltd.), dihydromyricetin (Nanjing Zeron medicine science and technology Co., Ltd.), and water as redistilled water.
Electronic balance (AL104, mettler-toledo instruments ltd), thermal-arrest thermostatically-heated stirrer (model DF-101S, engyu instrument factory, tou city), centrifuge (TDL-4, shanghai ann pavilion scientific instrument factory), UV-spectrophotometer (UV-5500PC, shanghai metaanalysis instruments ltd), small-angle X-ray scatterometer (SAXSess, austria, antopapa), fourier transform infrared spectrometer (AlphaT, Bruker Optik GmbH, Germany), gold leaf brand automatic double-pure water distiller (SZ-93A, shanghai asian honor biochemical instrument factory).
The invention will be further illustrated by the following examples
For the preparation of the support
Example 1
The surfactant/oil/water ratio was 44/11/45, the chitosan mass fraction was 4%, Tween80 and WCS (as surfactant) were weighed and placed in a colorimetric cylinder, and chitosan was uniformly dispersed in Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, the water content is increased at intervals of 2%, stirring uniformly by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the polyChanges in the phase and appearance of the aggregates require extended equilibration times when the phase boundaries are approached. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S1
Example 2
The surfactant/oil/water ratio is 44/11/45, the chitosan mass fraction is 8%, Tween80 and WCS (as surfactant) are weighed and placed in a colorimetric cylinder, and the mixture is uniformly mixed to uniformly disperse the chitosan in the Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, wherein the water content is increased at intervals of 2%, uniformly stirring by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the changes of the phase state and appearance of the aggregate, and prolonging the balancing time of the aggregate when the colorimetric tube is close to a phase boundary. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S2。
Comparative example 1
The surfactant/oil/water ratio is 44/11/45, the chitosan mass fraction is 0%, Tween80 and WCS (as surfactant) are weighed and placed in a colorimetric cylinder, and the mixture is uniformly mixed to uniformly disperse the chitosan in the Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, wherein the water content is increased at intervals of 2%, uniformly stirring by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the changes of the phase state and appearance of the aggregate, and prolonging the balancing time of the aggregate when the colorimetric tube is close to a phase boundary. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S0。
Example 3
The ratio of the surfactant to the oil is 9:1, the mass fraction of the chitosan is 4.5%, the water content is 45%, Tween80 and WCS (serving as the surfactant) are weighed and placed in a colorimetric tube, and the mixture is uniformly mixed to uniformly disperse the chitosan in the Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube to obtain the water contentThe aggregates were homogenized at 2% intervals using a magnetic stirrer and then equilibrated in a water bath at 25 c, and changes in phase and appearance of the aggregates were observed and recorded, requiring extended equilibration times as phase boundaries were approached. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S1O2.
Example 4
The ratio of the surfactant to the oil is 9.5:0.5, the mass fraction of the chitosan is 4.75%, the water content is 45%, Tween80 and WCS (as the surfactant) are weighed and placed in a colorimetric cylinder, and the mixture is uniformly mixed to uniformly disperse the chitosan in the Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, wherein the water content is increased at intervals of 2%, uniformly stirring by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the changes of the phase state and appearance of the aggregate, and prolonging the balancing time of the aggregate when the colorimetric tube is close to a phase boundary. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S1O3。
Example 5
The ratio of the surfactant to the oil was 8:2, the chitosan mass fraction was 3.71%, the water content was 49%, Tween80 and WCS (as surfactants) were weighed and placed in a colorimetric cylinder, and the mixture was uniformly mixed to disperse the chitosan uniformly in Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, wherein the water content is increased at intervals of 2%, uniformly stirring by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the changes of the phase state and appearance of the aggregate, and prolonging the balancing time of the aggregate when the colorimetric tube is close to a phase boundary. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S1W2。
Example 6
The surfactant to oil ratio was 8:2, the chitosan mass fraction was 3.42%, the water content was 53%, Tween80 and WCS (as surface) were weighedActive agent) and placed in a colorimetric tube, and uniformly mixed to uniformly disperse the chitosan in the Tween 80. IPM was added and mixed well under stirring in a water bath at 65 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, wherein the water content is increased at intervals of 2%, uniformly stirring by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the changes of the phase state and appearance of the aggregate, and prolonging the balancing time of the aggregate when the colorimetric tube is close to a phase boundary. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. Is marked as S1W3。
Drawing of phase diagrams
Tween80 and WCS (as surfactant) are weighed according to a certain mass ratio (10:1 or 9:2) and placed in a colorimetric tube, and chitosan is uniformly dispersed in the Tween80 after uniform mixing. Secondly, sequentially adding IPM into the surfactant according to the change of the oil phase ratio of the surfactant from 10:0 to 0:10, and stirring and uniformly mixing in a water bath at 60-70 ℃. Finally, adding redistilled water dropwise into the colorimetric tube, wherein the water content is increased at intervals of 2%, uniformly stirring by using a magnetic stirrer, then placing the colorimetric tube in a water bath at 25 ℃ for balancing, observing and recording the changes of the phase state and appearance of the aggregate, and prolonging the balancing time of the aggregate when the colorimetric tube is close to a phase boundary. The phase boundaries are initially judged by visual inspection of the color, clarity, hardness, viscosity, etc. exhibited by the aggregate. As shown in fig. 1.
Small angle X-ray scattering test
The small-angle X-ray scatterometer selects a copper target as a light source, the wavelength of an excited X-ray is 0.1542nm, the working voltage and the current are 40kV and 50mA respectively, the distance between a sample and a detector is 264.5nm, and the test needs to be carried out under the vacuum condition to prevent air scattering. The measurements were carried out on the liquid crystal samples studied at 25 ℃. The SAXS spectrogram obtained by measurement can be used for determining the structure type of the lyotropic liquid crystal and analyzing the microstructure and corresponding structural parameters of the liquid crystal sample.
In vitro Release test of Dihydromyricetin
The in vitro release behavior of dihydromyricetin was studied by means of in vitro dialysis, first, approximately 0.5g of liquid crystal loaded with drug was weighed out and placed in a treated dialysis bag (small intestine casing). Next, it was placed in a beaker containing 60ml of LPBS buffer medium (containing 20 wt% ethanol), and then, magnetons were put into the beaker and stirred in a water bath of a magnetic heating stirrer at a constant temperature. Finally, 5mL of release medium was removed at regular intervals while 5mL of release medium was replenished to maintain a constant volume until drug release reached equilibrium. And measuring the absorbance of the DMY at the position of 289nm of the maximum absorption wavelength of the DMY by using an ultraviolet spectrophotometer, obtaining the concentration of the DMY according to the standard absorption curve of the DMY, and calculating the cumulative release rate of the DMY according to the following formula.
TABLE 1 nomenclature and composition of the samples
TABLE 2 in vitro Release kinetics parameters of Dihydromyricetin in samples
TABLE 3 Primary Release kinetics parameters of Dihydromyricetin in samples
The experimental results are as follows:
as shown in FIG. 1a, clear, transparent, no-flow and relatively viscous liquid crystal phase regions are found in the phase diagram, and the liquid crystal phase regions are preliminarily judged to be hexagonal liquid crystal. And the water content in this phase region varied from 20 to 60 wt%, with a maximum solubilized oil content of 32 wt%.
As shown in fig. 1b and 1c, a region with high viscosity and no flow when inverted appears in each phase diagram, and the transparency of the aggregates gradually decreases and the color gradually deepens as the content of chitosan increases. As the chitosan content increases, the phase region gradually moves to the high water content region, because under the conditions of high surfactant content and low water content, the water-soluble chitosan is not completely dissolved, so that the system does not form transparent ordered aggregates, and the phase region of the system becomes smaller and moves to the high water content region.
As shown in FIG. 2, sample S0Shows 3 Bragg peaks whose ratio of relative peak positions corresponds to
This indicates the relation of sample S0Belonging to a hexagonal liquid crystal structure. Sample S0After chitosan is introduced into a hexagonal liquid crystal structure, the liquid crystal formed by the system is not complete.
From fig. 1, it can be seen that chitosan has a tendency to gradually dissolve in the system. From FIG. 2, it can be seen that chitosan affects the content of each component in the system. While affecting the structure formed by the system. The structure of the system after the chitosan is added is not a hexagonal phase structure, but the formed new system is still a stable aggregate structure, and only moves towards the direction of the water phase, so that the gel-like state with the same appearance as that of the lyotropic liquid crystal, and the gel-like state is shiny, does not flow and has increased viscoelasticity.
FIG. 3 is a graph of DMY release profiles for samples constructed at different chitosan concentrations, as seen in the early release phase (<1000min), DMY in sample S0,S1And S2The release rate in (1) is faster, mainly due to the release of DMY located in the interface layer. As the release proceeds, the release rate gradually slows, eventually reaching equilibrium and the cumulative release rate reaches a maximum. It was found that the release rate of DMY in the hexagonal phase liquid crystal was significantly decreased as the concentration of chitosan was increased during the entire release period, and DMY was in sample S2The medium release rate was the slowest, probably due to the high chitosan content, with the sample havingHigher elasticity and more stable structure, resulting in slower release rate of DMY. The result shows that the introduction of chitosan increases the stability of the drug-loaded sample, prolongs the release time of DMY in the sample, and has good slow release effect on DMY, so that the release behavior can be regulated and controlled through the introduction of chitosan.
FIG. 4a is a graph showing the release profile of DMY in samples of different surfactants/oils, as seen from the graph, in comparison with sample S1O2And S1O3In contrast, DMY was in sample S1O1The faster release rate is probably due to the swelling of the hydrophobic core, the loose structure of the aggregates and the decrease of the elasticity with increasing oil content.
As shown in fig. 4b, it can be seen that the release rate of DMY is slowed down with the increase of water content, and the chitosan is fully stretched in the aggregate, so that the release of DMY can be prevented to slow down the release rate and the cumulative release rate, and the aggregate can have better slow-release effect by increasing the water content.
From fig. 3 and 4, it can be seen that the oil content, chitosan content and water content affect the release behavior of DMY.
As shown in fig. 5. It can be seen that the release rates of DMY in the samples were significantly different at different pH values, with cumulative release rates of 90% (pH 7.4) and 99% (pH 5.6), respectively. Release media of different pH were formulated by controlling the amount of added sodium dihydrogen phosphate and disodium hydrogen phosphate. From FIG. 5, it can be seen that pH affects the DMY release behavior.
To investigate the DMY release behavior in aggregates, we used sample S0-S2For example, different kinetic models were fitted, mainly including a Zero-order kinetic model (Zero-order), a First-order kinetic model (First-order), a Higuchi model, a Hixson-Crowell model and a Korsmeyer-Peppas model, with the kinetic parameters obtained as shown in table 2. The maximum correlation (R) obtained using first order kinetic fitting was found2>0.9935) indicating that the release of DMY in the sample is a concentration-diffusion dependent process. Correlation (R) obtained by Korsmeyer-Peppas model2>0.9316) was only after the first order kinetics, indicating that the release of DMY from the liquid crystal sample most closely followed the first order kinetics.
The first order kinetic equation is as follows:
wherein K is a kinetic constant; n is a release index for characterizing the release mechanism of the drug; m0/MtIs the percent of drug released at time t.
And further selecting a first-order kinetic equation to fit all samples, wherein the obtained fitting equation and related parameters are shown in a table 3. Comparing the obtained correlation coefficients (R)2) The correlation R obtained by the first-order dynamic model fitting is found2Both are greater than 0.9920, indicating that the in vitro release behavior of DMY is more consistent with the first order kinetic model, indicating that the in vitro release process is controlled by concentration diffusion.
As can be seen from FIG. 6a, the-OH peak position was from 3384cm after introduction of chitosan into the system-1(S0) Down peak 3374cm-1(S1) The migration indicates that more hydrogen bonds are formed in the system, i.e. the introduction of chitosan is beneficial to the formation of hydrogen bonds and the stabilization of aggregates, which is consistent with the slow release rate and cumulative release rate caused by high content of chitosan in the in vitro release behavior. Wherein the thickness is 2851cm-1At a position of 2923cm-1The absorption peak is-CH on the alkyl chain of each component2Symmetric stretching vibration and antisymmetric stretching symmetric peak. 1461cm-1The position is a bending vibration absorption peak of C-H on an alkyl chain. At 1739cm-1Has an absorption peak, which is mainly generated by a stretching vibration peak of-C ═ O in a DMY molecule. 1643cm-1is-NH in chitosan21437cm from the peak of absorption of stretching vibration-1Is the stretching vibration peak of-N-H in chitosan, and is 1091cm-1The absorption peak at (A) is the stretching vibration peak of Tween80 and-C-O in DMY molecules.
From FIG. 7 can be seenIt is seen that the stretching vibration peak position of-OH is from 3376cm-1Variation 3374cm-1Indicating that more hydrogen bonds are formed in the system. Increasing the water content, it was found that the-OH peak was broadened, indicating that the increase in water content favors the formation of hydrogen bonds and the sample structure is more stable, consistent with the result that increasing the water content results in slower release rates.
To summarize:
the medicament prepared by the application has a good slow release effect on DMY. The in vitro release behavior of DMY is in accordance with the first order kinetic model, which indicates that the in vitro release process is controlled by concentration diffusion. Chitosan in the medicament influences the release behavior of DMY, oil content influences the release of DMY, water content influences the release of DMY, and the pH value of the system also influences the release of DMY. The coordination and coordination of the components of the medicament prepared herein may achieve the effect of controlling the release rate of the DMY drug.
Firstly, a lyotropic liquid crystal is constructed based on Tween80 to improve the solubility of dihydromyricetin, and the microemulsion solute liquid crystal with a certain microstructure and solubilization capacity has higher viscosity; the introduction of the chitosan which is non-toxic and has various physiological functions participates in the construction of the aggregate, the viscosity and the stability of the aggregate are increased by the introduction of the chitosan, and the influence of the introduction of the chitosan on the behaviors such as lyotropic liquid crystal phase behavior, release and the like is further researched.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (7)
1. A dihydromyricetin preparation based on Tween80 and chitosan aggregate as carrier comprises dihydromyricetin, Tween80, chitosan, isopropyl myristate (IPM) and water; the carrier system comprises 34-44 parts of Tween80, 3.42-8 parts of chitosan, 2-11 parts of isopropyl myristate and 45-53 parts of water;
the pH value of the medicament is 7.4;
the concentration of the dihydromyricetin is 1.5 mg/g;
the solubility of the chitosan is 0.04 g/g;
the water is double distilled water.
2. A method for preparing a dihydromyricetin pharmaceutical formulation as claimed in claim 1, wherein: the method comprises the following specific steps:
1) stirring and uniformly mixing Tween80 and IPM in a water bath according to a certain mass ratio;
2) adding dihydromyricetin into the mixture obtained in the step 1), and stirring and uniformly mixing in a water bath;
3) adding chitosan into the mixture obtained in the step 2), mixing and placing the mixture into a colorimetric tube, and uniformly dispersing the chitosan into Tween 80;
4) dropwise adding secondary distilled water into the colorimetric tube obtained in the step 3), uniformly stirring by using a magnetic stirrer, and then placing in a water bath for balancing to obtain the medicament.
3. The method for preparing dihydromyricetin pharmaceutical preparation according to claim 2, wherein: the mass ratio of the Tween80 to the chitosan in the step 3) is 9: 2-10: 1.
4. The method for preparing dihydromyricetin pharmaceutical preparation according to claim 2, wherein: the temperature of the step 1) is 60-70 ℃.
5. The method for preparing dihydromyricetin pharmaceutical preparation according to claim 2, wherein: the temperature of the water bath in the step 2) is 25 ℃.
6. The method for preparing dihydromyricetin pharmaceutical preparation according to claim 2, wherein: and adding water for multiple times in the step 4).
7. The method for preparing dihydromyricetin pharmaceutical preparation according to claim 6, wherein: in the step 4), the mass of the water is averagely divided into a plurality of parts, and the mass part of the water added each time is two parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810123231.XA CN108144064B (en) | 2018-02-07 | 2018-02-07 | Dihydromyricetin medicament taking aggregate of Tween80 and chitosan as carrier and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810123231.XA CN108144064B (en) | 2018-02-07 | 2018-02-07 | Dihydromyricetin medicament taking aggregate of Tween80 and chitosan as carrier and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108144064A CN108144064A (en) | 2018-06-12 |
| CN108144064B true CN108144064B (en) | 2021-01-08 |
Family
ID=62457220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810123231.XA Active CN108144064B (en) | 2018-02-07 | 2018-02-07 | Dihydromyricetin medicament taking aggregate of Tween80 and chitosan as carrier and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108144064B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010271B (en) * | 2018-09-25 | 2021-06-25 | 山东师范大学 | Apigenin slow-release type drug carrier and preparation method thereof |
| CN110037982B (en) * | 2019-04-17 | 2021-12-03 | 山东师范大学 | Dihydromyricetin lyotropic liquid crystal preparation and preparation method thereof |
| CN113616797B (en) * | 2021-08-03 | 2024-02-09 | 山东师范大学 | Low-water-solubility polyphenol drug carrier and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007028256A2 (en) * | 2005-09-09 | 2007-03-15 | Les Biotechnologies Oceanova Inc. | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation |
| CN101129373A (en) * | 2007-08-16 | 2008-02-27 | 华中师范大学 | Method for preparing Imiquimod chitosannano granule |
| CN101173026A (en) * | 2007-11-26 | 2008-05-07 | 天津科技大学 | AKD emulsion and method for producing the same |
| CN101596169A (en) * | 2009-07-06 | 2009-12-09 | 浙江大学 | A kind of chitosan nano of encapsulating adenosine triphosphate and preparation method |
-
2018
- 2018-02-07 CN CN201810123231.XA patent/CN108144064B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007028256A2 (en) * | 2005-09-09 | 2007-03-15 | Les Biotechnologies Oceanova Inc. | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation |
| CN101129373A (en) * | 2007-08-16 | 2008-02-27 | 华中师范大学 | Method for preparing Imiquimod chitosannano granule |
| CN101173026A (en) * | 2007-11-26 | 2008-05-07 | 天津科技大学 | AKD emulsion and method for producing the same |
| CN101596169A (en) * | 2009-07-06 | 2009-12-09 | 浙江大学 | A kind of chitosan nano of encapsulating adenosine triphosphate and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| Construction, in vitro release and rheological behavior of apigenin-encapsulated hexagonal liquid crystal;Li Zhang et al.;《Journal of Drug Delivery Science and Technology》;20170915;第2017卷(第41期);第475-481页 * |
| 药物有序聚集体的释放行为及性能;范军;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;20170315;第16、49-71页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108144064A (en) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108144064B (en) | Dihydromyricetin medicament taking aggregate of Tween80 and chitosan as carrier and preparation method thereof | |
| Khan et al. | Topical delivery of erythromycin through cubosomes for acne | |
| dos Santos et al. | A chitosan hydrogel-thickened nanoemulsion containing Pelargonium graveolens essential oil for treatment of vaginal candidiasis | |
| Uppal et al. | Chitosan nanoparticles as a biocompatible and efficient nanowagon for benzyl isothiocyanate | |
| Tang et al. | Fabrication of ultrastable water-in-oil high internal phase emulsion as versatile delivery vehicle through synergetic stabilization | |
| Li et al. | Enhancing the oxidative stability of algal oil powders stabilized by egg yolk granules/lecithin composites | |
| Pillai et al. | Solubilization and interaction of cinnamic acid and its analogues with Pluronic® micelles | |
| JP2013166778A (en) | Glycerol suspension of ascorbic acid | |
| CN108113964B (en) | Construction of Tween 80-based biocompatible microemulsion, in-vitro release of apigenin and research on antioxidant performance | |
| Begum et al. | Formulation and evaluation of dasatinib loaded solid lipid nanoparticles | |
| CN108478550B (en) | Medicine carrier based on alkyl glycoside lyotropic liquid crystal and preparation method and application thereof | |
| Yang et al. | Hepatotoxicity induced by ZnO quantum dots in mice | |
| DE69903436T2 (en) | POLYIONIC HYDROGELS BASED ON CHITOSAN AND XANTHAN GUM FOR THE STABILIZATION AND CONTROLLED RELEASE OF VITAMINS | |
| Yao et al. | Emulsifying properties of Chinese quince seed gum in oil-in-water emulsions | |
| CN108309954A (en) | A kind of the lecithin aliphatic radical reversed hexagonal liquid crystal medicament and preparation method of tea polyphenols | |
| CN104306389A (en) | Lincomycin-spectinomycin compound nano-emulsion | |
| Baharvandi et al. | Evaluation of the efficacy of amphotericin B and terbinafine microemulsions and their combination on cutaneous leishmaniasis and comparison with the conventional drug form in BALB/c mice | |
| CN109010271B (en) | Apigenin slow-release type drug carrier and preparation method thereof | |
| CN109125267B (en) | Preparation method and in-vitro release performance of lyotropic liquid crystal carrier with curcumin protection effect | |
| CN108785682B (en) | Lipid carrier with slow release effect on low-water-solubility polyphenol drugs and preparation method and application thereof | |
| CN109248148B (en) | Preparation and in vitro release of dihydromyricetin lecithin-based liquid crystal dispersion particles, antioxidant and cytotoxic effects | |
| Buachi et al. | Encapsulation of propolis extracts in aqueous formulations by using nanovesicles of lipid and poly (styrene-alt-maleic acid) | |
| MHATRE et al. | Formulation, development and evaluation of topical emulgel of griseofulvin | |
| CN113616797B (en) | Low-water-solubility polyphenol drug carrier and preparation method and application thereof | |
| CN111939128A (en) | Temperature-sensitive lyotropic liquid crystal drug carrier and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240326 Address after: 2081, building a, 88 Jianghai West Road, Liangxi District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Xiangyuan Information Technology Co.,Ltd. Country or region after: China Address before: 250014 No. 88, Wenhua East Road, Lixia District, Shandong, Ji'nan Patentee before: SHANDONG NORMAL University Country or region before: China |